GlassScriptPhysician profile
Naveen Reddy
NPI 1134292154
$3,610.62
in general payments reported to CMS, 2019-2025
30 companies · $929 in 2025
The $929 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48.79 · 2020: $13.89 · 2021: $250 · 2022: $585 · 2023: $774 · 2024: $1,010 · 2025: $929.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,668 · Education: $44.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,667.95 |
| Education | $44.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,084.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $478.27 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $445.78 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $191.21 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $167.00 | 2020-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $145.11 | 2022-2024 | Zeposia |
| Celgene Corporation | $115.53 | 2021-2023 | Zeposia |
| Pfizer INC. | $96.00 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $93.00 | 2022-2023 | Dificid |
| Aimmune Therapeutics, INC. | $91.82 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $85.52 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $78.89 | 2025 | Omvoh |
| Qol Medical, LLC | $59.19 | 2023-2025 | Sucraid |
| Nestle Healthcare Nutrition INC. | $56.14 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $55.65 | 2023 | Idacio |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $44.06 | 2022-2023 | Injectafer |
| Genzyme Corporation | $43.77 | 2024 | |
| Phathom Pharmaceuticals, INC. | $40.05 | 2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.49 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $26.06 | 2025 | |
| Braintree Laboratories, INC. | $24.81 | 2022 | |
| Celltrion USA INC. | $23.04 | 2025 | Vegzelma |
| Gilead Sciences, INC. | $22.56 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $21.90 | 2024 | Iqirvo |
| Pacira Pharmaceuticals Incorporated | $18.32 | 2023 | Exparel, Zilretta |
| Organon LLC | $16.87 | 2023 | Renflexis, Hadlima |
| Madrigal Pharmaceuticals | $15.76 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $14.57 | 2023 | Gimoti |
| Capsovision, INC. | $14.16 | 2024 | Capsocam Plus |
| Vivus LLC | $13.35 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveen Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.